{"id":9120,"date":"2019-04-03T08:00:00","date_gmt":"2019-04-03T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/"},"modified":"2019-04-03T08:00:00","modified_gmt":"2019-04-03T06:00:00","slug":"irlab-therapeutics-ab-publicerar-arsredovisning-for-2018","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/","title":{"rendered":"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2018 finns tillg\u00e4nglig p\u00e5 bolagets hemsida, www.irlab.se\/investor-relations\/financial-reports\/.<\/strong><\/div>\n
\u00c5rsredovisningen \u00e4r uppr\u00e4ttad p\u00e5 svenska och kommer att finnas tillg\u00e4nglig p\u00e5 engelska.<\/p><\/pre>\n
\n
F\u00f6r vidare information<\/strong><\/p>\n
Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n
Viktor Siewertz, CFO\u00a0
Tel: +46 727 10 70 70\u00a0
E-post: viktor.siewertz@irlab.se<\/a><\/p>\n
FNCA Sweden AB, +46 8 528 00 399; info@fnca.se<\/a>, \u00e4r Bolagets Certified Adviser p\u00e5 Nasdaq First North Premier.<\/p>\n<\/div>\n
\n
Om IRLAB<\/strong><\/p>\n
IRLAB \u00e4r ett svenskt biotechbolag fokuserat p\u00e5 Parkinsons sjukdom. Bolagets kliniska Fas II-kandidater, IRL752 och IRL790, \u00e4mnar behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinsons sjukdom: ofrivilliga r\u00f6relser (LIDs), psykos och demens. Genom den propriet\u00e4ra forskningsplattformen ISP (Integrative Screening Process) uppt\u00e4cker och utvecklar IRLAB l\u00e4kemedelskandidater f\u00f6r sjukdomar relaterade till det centrala nervsystemet (CNS) d\u00e4r stora v\u00e4xande medicinska behov f\u00f6religger. F\u00f6rutom de kliniska kandidaterna har ISP-plattformen dessutom genererat flera CNS-program som nu \u00e4r i preklinisk fas. IRLAB:s Certified Adviser p\u00e5 Nasdaq First North \u00e4r FNCA Sweden AB, info@fnca.se, 08-528 00 399. Mer information p\u00e5 www.irlab.se<\/a>.<\/p>\n<\/div>\n
[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"
IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2018 finns tillg\u00e4nglig p\u00e5 bolagets hemsida, www.irlab.se\/investor-relations\/financial-reports\/.<\/p>\n","protected":false},"template":"","class_list":["post-9120","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"\nIRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2018 finns tillg\u00e4nglig p\u00e5 bolagets hemsida, www.irlab.se\/investor-relations\/financial-reports\/.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/\",\"name\":\"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2019-04-03T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB","og_description":"IRLAB meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2018 finns tillg\u00e4nglig p\u00e5 bolagets hemsida, www.irlab.se\/investor-relations\/financial-reports\/.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/","name":"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2019-04-03T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publicerar-arsredovisning-for-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB Therapeutics AB publicerar \u00e5rsredovisning f\u00f6r 2018"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}